IL10 and acute myeloid leukemia: The manipulation of networks such as the co-inhibitory PD-1–PD-L1 pathway and suppressor IL-10–IL-10R pathway could be an attractive and novel immunotherapeutic intervention for AML patients ineligible for standard treatment with chemotherapy and hematopoietic stem cell transplantation.